// App-Quantinova.ai

: Day 100 Peripheral Blood Natural Killer Cell/CD14+HLA-DR- Ratio Predicts Clinical Outcomes in Lymphoma Patients Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Researchers

Presenter

  • Luis F. Porrata

Principal Investigators

  • David J. Inwards

  • Stephen M. Ansell

  • Ivana N. Micallef

  • Patrick B. Johnston

  • Jose C. Villasboas

  • Jonas Paludo

  • Urshila Durani

  • Svetomir N. Markovic

Medical Centers

  • Division of Hematology, Mayo Clinic, ROCHESTER, MN

  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Natural Killer cells

  • Cluster of Differentiation 14

  • Cluster of Differentiation 34

  • Human Leukocyte Antigen – DR isotype

  • Apparent diffusion coefficient

Drug/Treatment

  • Plerixafor

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved